MapLight Therapeutics, Inc. Research and Development Expense
MapLight Therapeutics, Inc. (MPLT) reported Research and Development Expense of $53.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- MapLight Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $53.44M, a 99.04% increase year-over-year.
- MapLight Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $53.68M, a 171.31% increase year-over-year.
- MapLight Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $64.62M, a 211.99% increase year-over-year.
- MapLight Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $27.09M, a 61.14% increase year-over-year.
- MapLight Therapeutics, Inc. research and development expense for fiscal 2025 was $138.35M, a 101.90% increase from fiscal 2024.
- MapLight Therapeutics, Inc. research and development expense for fiscal 2024 was $68.52M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $53.44M 10-Q · filed 2026-08-13 | $107.12M 10-Q · filed 2026-08-13 | $171.74M derived: sum of 3 quarters · filed 2026-08-13 | $198.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $53.68M 10-Q · filed 2026-05-14 | $118.31M derived: sum of 2 quarters · filed 2026-05-14 | $145.40M derived: sum of 3 quarters · filed 2026-05-14 | $172.25M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $64.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $91.72M derived: sum of 2 quarters · filed 2026-03-26 | $118.56M derived: sum of 3 quarters · filed 2026-08-13 | $138.35M 10-K · filed 2026-03-26 |
| 2025-09-30 | $27.09M 10-Q · filed 2025-12-04 | $53.94M derived: sum of 2 quarters · filed 2026-08-13 | $73.73M 10-Q · filed 2025-12-04 | $94.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $26.85M 10-Q · filed 2026-08-13 | $46.63M 10-Q · filed 2026-08-13 | $67.35M derived: sum of 3 quarters · filed 2026-08-13 | $84.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $19.79M 10-Q · filed 2026-05-14 | $40.50M derived: sum of 2 quarters · filed 2026-05-14 | $57.31M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $20.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $37.53M derived: sum of 2 quarters · filed 2026-03-26 | $68.52M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $16.81M 10-Q · filed 2025-12-04 | $47.81M 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |